Stocksigma LogoStocksigma Logo

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million

Evonile Pharma Limited (formerly Novartis India Limited) approved raising funds up to ₹9,000 million via a rights issue of partly paid-up equity shares

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million

Novartis India Ltd · Rights Issue · 09 Oct 2026, 12:36 am

Evonile Pharma Approves Rights Issue of Up to ₹9,000 Million Evonile Pharma Limited (formerly Novartis India Limited) approved raising funds up to ₹9,000 million via a rights issue of partly paid-up equity shares (face value ₹5 each) on 8th Oct'26, subject to regulatory and shareholder approvals via postal ballot. The Board constituted a Rights Issue Committee comprising MD & CEO Vikas Gupta, Non-Executive Director Dr. Jagriti Gupta, and Independent Director Shashank Sinha to determine key terms, including issue size, entitlement ratio, issue price, and record date. Additionally, the company launched its new corporate website.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements